Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
This is a classic Item 5.07 disclosure reporting the final results of Capricor's Annual Meeting of stockholders held on June 4, 2026. The filing presents detailed voting tallies for all five proposals, including election of eight directors, ratification of auditors, advisory votes on executive compensation and frequency, and a failed amendment to the Certificate of Incorporation. Shareholder vote results are material to investors as they determine board composition and governance matters.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-08
Item 8.01
The filing discloses an all-stock merger-of-equals transaction between AvalonBay Communities and Equity Residential, previously announced on May 20, 2026, with a joint press release on June 8, 2026 announcing the combined company's executive leadership team. This is a material acquisition/change of control event that would substantially affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Jefferson Capital's Annual Meeting of Stockholders held on June 5, 2026. The filing presents voting tallies for two proposals: election of three Class I directors (David Burton, Thomas Harding, and Thomas Lydon, Jr.) and ratification of Deloitte & Touche LLP as independent auditor. All proposals passed with substantial majorities. Shareholder vote results are material to investors as they confirm board composition and auditor appointment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-08
Item 8.01
The filing discloses the closing of a series of local asset purchase agreements whereby Senseonics acquired Ascensia's Eversense CGM commercial assets in four European countries (Italy, Germany, Spain, and Sweden). The closings occurred on June 1-8, 2026, following satisfaction of customary closing conditions. This constitutes completion of a material acquisition of assets and represents a significant M&A transaction requiring 8-K disclosure under Item 1.01/2.01.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 7.01
The disclosure announces the redemption deadline for FGMC's public stockholders in connection with the business combination with BOXABL Inc. While the redemption deadline itself is a procedural milestone, it is material to investors as it represents a critical juncture in the SPAC merger process that affects shareholder rights and the capital structure of the combined entity. This does not fit neatly into the M&A activity category (which typically covers entry, completion, or termination of the transaction itself) but rather represents a material procedural event within an ongoing M&A transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Innodata's Annual Meeting of Stockholders held on June 4, 2026. The filing reports voting outcomes for four proposals: election of five directors, ratification of BDO India Services as independent auditors, advisory approval of named executive officer compensation, and approval of the Amended and Restated Equity Compensation Plan. All proposals passed with substantial majorities, making this a material governance event that investors rely upon to assess board composition and executive accountability.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
Liquidia Corporation announced its addition to the S&P SmallCap 600® Index effective June 22, 2026. Index inclusion is a material corporate event that typically increases visibility, liquidity, and institutional investor interest in the stock, affecting the total mix of information available to investors. While not fitting neatly into the standard taxonomy categories, this disclosure warrants classification as a material event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-08
Item 1.01
This Item 1.01 discloses entry into an amended and restated business combination agreement between Spring Valley Acquisition Corp. III (SPAC) and General Fusion Inc., with the second amendment executed on June 3, 2026. The filing describes a material acquisition/merger transaction involving SPAC continuation, amalgamation of NewCo with the SPAC, and change of control, which are quintessential M&A activities under Item 1.01.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 1.01
FS KKR Capital Corp entered into a Sixteenth Supplemental Indenture on June 8, 2026 to issue $900 million in 7.500% notes due 2031, generating approximately $890 million in net proceeds. This represents a significant debt issuance and capital raise that materially increases the company's debt obligations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-08
Item 5.02
The filing discloses the election of Mark A. Edmunds as a director and his appointment as Chair of the Audit and Finance Committee and member of the Cyber and Technology Oversight Committee, effective immediately on June 8, 2026. While the section also includes Silvia Davila's resignation, the principal disclosed action centers on the appointment of a new director to key committee roles. Director appointments to significant committee positions are material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Alarm.com's June 3, 2026 Annual Meeting of Stockholders. The filing reports final voting tallies on three proposals: election of eight directors, ratification of PricewaterhouseCoopers LLP as auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely on to assess board composition and management accountability.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-08
Item 5.02
William Reinhardt's retirement from the Board of Metropolitan Bank Holding Corp. and its subsidiary Metropolitan Commercial Bank, effective immediately on June 6, 2026, constitutes a departure of a director. While the disclosure also mentions his honorary designation as director emeritus, the principal disclosed action is his departure from the board, which is material to investors assessing the composition and governance of the registrant.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-08
Item 3.02
Elite Express completed a private placement of 32,000,000 shares of Class A Common Stock at $0.25 per share for $8,000,000 in gross proceeds on June 4, 2026, conducted offshore under Regulation S to non-U.S. investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-08
Item 5.02
Ye Hua was appointed as Chief Financial Officer effective June 8, 2026, bringing CPA credentials, a Master's in Accountancy, and prior tax and accounting experience to the role.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-08
Item 5.02
The filing discloses amended and restated employment agreements for three named executives (William Santana Li, Apoorv S. Dwivedi, and Mercedes Soria) that establish new base salaries, annual bonus targets, performance-based cash awards with aggregate target values of $65M, $35.75M, and $22.75M respectively, severance arrangements, and stock option grants. This is a comprehensive compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure, and materially affects investor assessment of executive incentives and potential future obligations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-08
Item 2.02
The filing explicitly discloses that on June 8, 2026, Motorcar Parts of America issued a press release announcing earnings for the fiscal quarter and year ended March 31, 2026, with the press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, and earnings announcements are material to investors' assessment of the company's financial performance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-08
Item 7.01
The filing discloses an Agreement and Plan of Merger entered into on May 2, 2026, whereby Global Business Travel Group is to be acquired by Long Lake Management through Parent and Gaia Merger Sub. The June 8, 2026 disclosure provides financial metrics to prospective lenders in connection with the debt financing for this transaction. This is a material acquisition/change of control event, even though disclosed under Item 7.01 (Regulation FD Disclosure) rather than the more typical Item 1.01 or 2.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-08
Item 1.01
While Item 1.01 formally covers the Settlement Agreement with Helena, the disclosure's material substance centers on the proposed three-way business combination among DevvStream, XCF Global, and Southern Energy Renewables. The settlement itself—resolving a $10M convertible note dispute—is material, but the filing's extensive discussion of merger consent, Section 13 waiver survival, and repeated references to the "proposed business combination transaction" indicate that the M&A activity (the merger) is the primary material event driving this disclosure. The settlement is largely a prerequisite to clearing the path for the merger to proceed.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-08
Item 5.02
Ludwig N. Hantson was appointed to the Board of Directors of Ionis Pharmaceuticals effective June 4, 2026. Hantson brings 30+ years of biopharmaceutical leadership experience, including prior CEO roles at Alexion and Baxalta.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
Ionis Pharmaceuticals held its Annual Meeting of Stockholders on June 4, 2026, with voting results disclosed for five proposals: director elections (Berthelsen and Herman), advisory compensation vote, equity plan amendment (9.5M shares), employee stock purchase plan amendment, and auditor ratification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-08
Item 5.02
The filing discloses the appointment of Tim Nauss as a Class II director of CarParts.com, Inc., effective immediately, to serve until the 2029 Annual Meeting. The Board increased its size to seven directors to accommodate this appointment. While the disclosure mentions standard director compensation ($50,000 annual retainer), the principal action is the appointment itself, not a compensation arrangement. This is material as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-08
Item 5.02
Stanley J. Sutula III was appointed as a director effective June 4, 2026, expanding the Board from eleven to twelve members and joining the Audit Committee. Director Cara Heiden retired concurrently. The appointment represents a material change to board composition and committee oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
This Item 5.07 disclosure reports the results of AtaiBeckley Inc.'s annual meeting of stockholders held on June 4, 2026, including voting outcomes for the election of three Class I directors (Sabrina Martucci Johnson, Amir Kalali, M.D., and Andrea Heslin Smiley) and ratification of Deloitte & Touche LLP as independent auditor. The filing explicitly states all three nominees were elected and Proposal 2 was approved, making this a standard shareholder vote results disclosure that is material to investors' understanding of board composition and audit oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-08
Item 5.02
The filing discloses two executive events: the retirement of Jill Livesay (Vice President, Controller and Principal Accounting Officer) effective July 31, 2026, and the appointment of Enrique N. Mayor-Mora as Principal Accounting Officer effective upon Livesay's retirement. While both a departure and appointment occur, the principal disclosed action centers on the appointment of Mayor-Mora to the PAO role, with detailed background on his 15-year tenure and career progression at CarMax. The appointment of a principal accounting officer is material to investors as it affects financial reporting oversight and internal controls.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-08
The filing discloses unregistered sales of convertible promissory notes totaling $225,000 in principal (with $247,500 repayment obligation) under Item 3.02. The 2026 Bridge Notes are convertible into common stock at $0.15 per share and were sold pursuant to Section 4(a)(2) and Regulation D exemptions. Additionally, Item 8.01 describes a non-binding term sheet for a $30 million Equity Line of Credit (ELOC) facility with registration planned via Form S-1, indicating substantial dilutive equity issuance activity. This is material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
The filing discloses an amendment to extend IGC Pharma's Master Loan and Security Agreement with O-Bank Co., Ltd., increasing the facility fee from $48,000 to $60,000 while maintaining a $12,000,000 maximum aggregate limit. While Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of Direct Financial Obligation) are cited, this is a routine extension of an existing credit facility rather than a new material acquisition, debt covenant breach, or other specifically-defined event type. The modest fee increase and continuation of substantially unchanged terms suggest administrative renewal rather than a transformative financial event, though the extension of material debt facilities warrants disclosure as material to investors.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 8.01
The Board formed a Transformation Committee on June 5, 2026, to oversee a company-wide transformation initiative focused on business positioning, cost structure optimization, growth opportunities, capital allocation, and portfolio composition. While the disclosure does not fit neatly into standard categories like M&A, executive appointment, or compensation, the formation of a board committee with explicit oversight of strategic transformation, cost optimization, and capital allocation decisions would likely affect a reasonable investor's assessment of the company's strategic direction and financial priorities. This is material governance activity related to significant business strategy changes, but lacks the specificity of other event types.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-08
Item 8.01
Cullinan Therapeutics announced initial Phase 1 clinical trial data for CLN-978 in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients from the OUTRACE trials, showing clinical activity with 71% of SLE patients achieving ≥4-point hSLEDAI reduction and 71% of RA patients demonstrating disease activity improvement, along with B cell depletion biomarker results. The data was presented at EULAR, a major rheumatology conference, and materially affects investor assessment of the company's pipeline development trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-08
Item 2.02
The filing discloses Duluth Holdings' financial results for its fiscal first quarter ended May 3, 2026, through an Earnings Press Release furnished as Exhibit 99.1. Item 2.02 explicitly covers "Results of Operations and Financial Conditions," and the prose confirms the Company issued a press release "discussing, among other things, its financial results for its fiscal first quarter." This is a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-08
Item 8.01
Palladyne AI entered into a Memorandum of Understanding with Israel Aerospace Industries granting exclusive manufacturing and marketing rights to loitering munitions systems (HAROP, HARPY, Mini-HARPY) for the U.S. government market, establishing a U.S. assembly line and multi-year commercial arrangement with defined royalty obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-08
Item 8.01
Ciena announced its intention to issue $2.0 billion of convertible senior notes due 2031 in a private placement under Rule 144A, with an additional $300 million option. The convertible notes are inherently dilutive securities that will convert to common stock, and the filing explicitly discloses concurrent warrant transactions relating to shares of common stock. This is a material capital-raising event typical of dilutive issuances at mid-cap technology companies.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-08
Item 2.02
Graham Corporation disclosed its results of operations and financial condition for the fourth quarter and fiscal year ended March 31, 2026 via a press release furnished as Exhibit 99.1, with accompanying presentation slides and supplemental data tables (historical sales, orders, and backlog) posted for an earnings conference call and webcast on June 8, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-08
Item 2.02
The filing discloses financial results for the three months ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides periodic financial performance data essential to assessing the registrant's operational and financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-08
Item 2.02
The filing discloses financial results for the fiscal first quarter ended April 30, 2026, via a press release attached as Exhibit 99.1. This is a standard quarterly earnings release under Item 2.02, which is material to investors as it provides periodic financial performance data essential to assessing the registrant's condition.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-08
Item 8.01
Tango Therapeutics disclosed initial safety and efficacy data from a Phase 1/2 combination trial of vopimetostat with RAS(ON) inhibitors, demonstrating strong efficacy signals (92% ORR in PDAC with daraxonrasib, 52% ORR with zoldonrasib) and favorable safety profiles. This clinical milestone data, which will advance the program to Phase 3 development, is material to investors' assessment of the company's pipeline and regulatory prospects.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-08
Item 1.01
Village Farms entered into securities purchase agreements on June 5, 2026 for a registered direct offering of 7,500,000 common shares at US$2.00 per share, generating approximately US$15 million in gross proceeds. This is a registered equity issuance that will dilute existing shareholders' ownership and is material to investors assessing the company's capital structure and financing activities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-08
Item 8.01
Strategy Inc sold 1,409,600 shares of Class A Common Stock under its at-the-market offering program during June 1-7, 2026, generating $181.0 million in net proceeds, with $25.956 billion remaining capacity under a $21.0 billion offering increase announced on March 23, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-08
Item 1.01
Fair Isaac entered into a material amendment to its credit agreement on June 5, 2026, adding a $1.5 billion unsecured incremental term loan maturing in 2028, with proceeds designated for an accelerated share repurchase program.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
Fair Isaac announced a new $2.0 billion stock repurchase program and entered into a $1.5 billion accelerated share repurchase (ASR) agreement with Wells Fargo Securities, with an upfront payment on June 8, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-08
Item 1.01
Paul Carreiro was appointed as President and Chief Executive Officer effective July 6, 2026, with a $500,000 base salary, performance bonus eligibility, and substantial equity grants including 1.06 million LTIP Units.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
A material commercial customer is terminating two contracted projects effective June 16, 2026, reducing annual recurring revenue by $2.7 million (73% of that customer's $3.7 million prior ARR), though the company is pursuing mitigation measures and recertification opportunities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-06-08
Item 8.01
The filing discloses results of a stockholder vote at the 2026 Annual Meeting of Stockholders held on June 8, 2026, where shareholders approved an amendment to the terms of the STRC preferred stock to change dividend payment frequency from monthly to semi-monthly. This is a shareholder vote result on a material corporate action affecting preferred stock terms.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
This is a clear disclosure of shareholder vote results from Ambiq Micro's 2026 Annual Meeting held on June 8, 2026, reporting final voting tallies for two proposals: election of Class I directors (Timothy Chen and Ker Zhang, Ph.D.) and ratification of KPMG LLP as independent auditor. The filing directly matches Item 5.07 requirements and is material to investors as it documents stockholder approval of board composition and audit firm selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
This is a clear disclosure of shareholder vote results from the June 5, 2026 Annual Meeting of Stockholders, reporting the outcomes of three proposals: election of three Class II directors (Jane Chung, Connie Matsui, and James Panek), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The tabulated voting results with shares for, against, withheld, and abstaining are the hallmark of Item 5.07 disclosure and constitute material information about corporate governance actions.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 7.01
Vor Biopharma announced that its partner RemeGen received conditional approval from China's NMPA for telitacicept in IgA nephropathy and full approval in Sjögren's disease. This represents a material regulatory milestone for a product in the company's pipeline, affecting investor assessment of the company's commercial prospects and partnership value. However, the event does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, or executive change), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
This is a clear disclosure of shareholder vote results from Red Rock Resorts' Annual Meeting of Stockholders held on June 4, 2026. The filing reports voting outcomes for three proposals: election of five directors (Frank J. Fertitta III, Lorenzo J. Fertitta, Robert A. Cashell Jr., Robert E. Lewis, and James E. Nave), a say-on-pay advisory vote, and ratification of Ernst & Young LLP as independent auditor. All proposals passed with majority support, making this a material disclosure of shareholder meeting outcomes required under Item 5.07.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
Mastercard completed a $5 billion debt offering across five tranches of notes with varying maturities and rates (2028–2036). While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the standard 8-K taxonomy. The disclosure is routine debt issuance under an existing S-3 registration statement, not a covenant breach, going-concern issue, or other acute financial stress signal. Classified as other_material because the magnitude and nature of the transaction would affect a reasonable investor's assessment of the company's financial position, but the event itself is a standard capital markets transaction rather than a discrete material event type.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-08
Item 5.07
This 8-K Item 5.07 discloses the final voting results from CG Oncology's June 4, 2026 Annual Meeting of Stockholders, including four proposals: election of two Class II directors (Christina Rossi and Victor Tong, Jr.), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. The disclosure presents detailed vote tallies for each matter, which is the core content of Item 5.07 shareholder vote results.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-08
Item 5.02
The board awarded success bonuses totaling $450,000 to four named executive officers (Douglas Kaye, David Johnson, Timothy Donnelly, and Shirin Khosravi) in recognition of their role in restructuring the Company's debt.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-06-08
Item 5.07
The Company held its 2026 Annual Meeting of Stockholders on June 3, 2026, with voting results reported for four proposals: election of seven directors (all elected with majority support), ratification of Deloitte Touche LLP as independent auditor, advisory vote on executive compensation frequency (1-year preference), and advisory approval of executive compensation policies.
View raw filing on EDGAR →